ICIs, immuno-oncologic agents that potentiate T cell-mediated anti-tumor immunity, have represented a major therapeutic advance particularly in advanced stage melanoma, non-small cell lung cancer (NSCLC), head and neck, and breast cancer, in relation with the levels of the programmed-death ligand 1 (PD-L1) expression [3,4,5,6]. The gene discussed is CD274; the disease is neoplasm.